Oribiotech
Meet Oribiotech at the UK Pavilion (Hall B, Stand 2348).
Ori is a London and New Jersey based manufacturing technology company pioneering flexible process discovery with seamless translation and scalable commercialization of cell and genetherapies. Ori has developed a proprietary, full stack manufacturing platform that closes, automates and standardizes CGT manufacturing allowing therapeutics developers to develop and bring their products to market at commercial scale. The promise of the innovative Ori platform is to fully automate CGT manufacturing to increase throughput, improve quality and decrease costs by combining proprietary hardware, software, data and analytics. Founded in 2015 by Dr. FarlanVeraitch (UCL), Ori has brought together a seasoned team with over 200 years of combined pharmaceutical, CGT and venture building experience including CEO Jason C. Foster (Indivior), CDOO Kevin Gordon (Tmunity), CTO Stuart Milne (Cytiva), CCO Tom Heathman (Minaris), Chris Mason (AVROBIO), Paul Meister (Thermo Fisher) and Annalisa Jenkins (DimensionTx) alongside expert advisers like Bruce Levine and Robert Preti.
Pangaea
Meet Pangaea at the UK Pavilion (Hall B, Stand 2348).
Pangaea is a South San Francisco and London based provider of a novel AI-driven product for characterizing patients across 4,000 hard-to-diagnose conditions in a privacy-preserving and scalable manner, which is helping clinicians in the pharmaceutical and healthcare industry. Pangaea has clinically proven to discover 22x more undiagnosed, misdiagnosed and miscoded patients along with new insights; halve treatment costs; and drive sustainable collaborations between healthcare and the pharmaceutical industry. The founders (Dr. Vibhor Gupta, Prof. Yike Guo) have attracted $200 million through research and are advised by Lord David Prior (former Chairman of NHS England), Mr. Andy Palmer (former Head of Systems Integration at Novartis) and Dr. Thomas Dyrberg (former Managing Partner, Novo Holdings). Pangaea was awarded top tier status by Microsoft, which is exclusive for 30 of the 30,000 companies they work with and has provided the opportunity to apply its product across 140,000 healthcare providers globally.
Phaim
Meet Phaim at the UK Pavilion (Hall B, Stand 2348).
Phaim is developing novel therapies for the treatment and early detection of autoimmune disease with a lead product in Type1 Diabetes. Phaim’s platform approach to autoimmunity will recapitulate the normal regulatory immune response, preventing the onset of T1DM in prediabetics, and facilitating the use of cellular therapies in the treatment of established T1DM patients. The platform has means of identifying targets in other autoimmune diseases, such as psoriasis and we would look to produce other therapies after our successful T1DM trial. Furthermore, with our proprietary diagnostic kit, we will be able to predict who is likely to get T1DM and in what time frame. By doing so, we could potentially treat before the disease develops and look to ameliorate the need for insulin. In short, Phaim canpredict, prevent and potentially treattype 1 diabetes and other autoimmune conditions. Phaim's T1D therapy alone has a potential of world-wide market capture.
